Example ImageÃÀ¸ß÷

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
Customer Center
¿Í»§ÖÐÐÄ

¡¾ÃÀ¸ß÷ÖúÁ¦¡¿°Ù°ÂÌ©µ¥¿¹×¢ÉäÒºBAT1308»ñµÃ¡¶ÁÙ´²ÊÔÑé֪ͨÊé¡·

2020-06-04
|
»á¼ûÁ¿£º

2020Äê5ÔÂ27ÈÕ£¬£¬£¬£¬£¬£¬°Ù°ÂÌ©ÉúÎïÖÆÒ©¹É·ÝÓÐÏÞ¹«Ë¾£¨ÒÔϼò³Æ¡°°Ù°ÂÌ©¡±£©Ðû²¼£¬£¬£¬£¬£¬£¬¹«Ë¾ÓÚ2020Äê05ÔÂ26ÈÕÊÕµ½¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÅú׼ǩ·¢µÄ¹ØÓÚ¹«Ë¾ÔÚÑÐÒ©Æ·BAT 1308×¢ÉäÒºµÄ¡¶ÁÙ´²ÊÔÑé֪ͨÊé¡·¡£ ¡£¡£¡£¡£¡£

BAT1308×¢ÉäÒºÊǰٰÂÌ©×ÔÖ÷Ñз¢µÄÒ»ÖÖµ¥¿¹Ò©Î£¬£¬£¬£¬£¬Æä»îÐÔÒòËØÊÇÒ»ÖÖÓÉÖйú²ÖÊóÂѳ²Ï¸°û±í´ïµÄÈ˳ÌÐòÐÔϸ°ûéæÃüÂѰ×1£¨PD-1£©µÄ¿¹Ì壬£¬£¬£¬£¬£¬ÊôÓÚÃâÒßÇòÂѰ×IgG4kÑÇÐÍ£¬£¬£¬£¬£¬£¬Äܹ»ÒÔ¸ßÇ׺ÍÁ¦ÌØÒìÐÔµØÁ¬ÏµÈËPD-1£¬£¬£¬£¬£¬£¬´Ó¶ø×è¶ÏPD-1ÓëÆäÅäÌåPD-L1¡¢PD-L2µÄÏ໥×÷Óᣠ¡£¡£¡£¡£¡£BAT1308Äܹ»ÓëTϸ°ûÍâòµÄPD-1Á¬Ïµ£¬£¬£¬£¬£¬£¬É¨³ýPD-1ͨ·¶ÔTϸ°ûµÄÒÖÖÆ×÷Ó㬣¬£¬£¬£¬£¬´Ó¶ø»Ö¸´ºÍÌá¸ßTϸ°ûµÄÃâÒßɱÉËÄÜÁ¦£¬£¬£¬£¬£¬£¬ÒÖÖÆÖ×ÁöÉú³¤¡£ ¡£¡£¡£¡£¡£

°Ù°ÂÌ©ÓÚ2020Äê02ÔÂ21ÈÕÉÏÊУ¬£¬£¬£¬£¬£¬ÖÂÁ¦ÓÚÐÂÒ»´ú¿¹ÌåÒ©ÎïµÄÑз¢£¬£¬£¬£¬£¬£¬ÓÃÒÔÖÎÁư©Ö¢£¬£¬£¬£¬£¬£¬×ÔÉíÃâÒßÐÔ¼²²¡£¬£¬£¬£¬£¬£¬ÐÄѪ¹Ü¼²²¡ÒÔ¼°ÆäËûΣ¼°ÈËÀàÉúÃü¿µ½¡µÄÖØ´ó¼²²¡¡£ ¡£¡£¡£¡£¡£

ÃÀ¸ß÷ÓÐÐÒÔÚµ¥¿¹BAT1308×¢Éä¼ÁµÄÑз¢ÖÐÓë°Ù°ÂÌ©ÏàÖú£¬£¬£¬£¬£¬£¬ÔÚGLP µÄʵÑéÊÒÇéÐκͲÙ×÷¹æ·¶Ï£¬£¬£¬£¬£¬£¬Íê³ÉÁËBAT1308µ¥¿¹×¢ÉäÒºµÄÒ©´ú¶¯Á¦Ñ§ºÍÇå¾²ÐÔÆÀ¼ÛÉ걨ÊÔÑé¡£ ¡£¡£¡£¡£¡£

ÃÀ¸ß÷ÁÙ´²Ç°Ñо¿Ð§ÀͳмÌÒÔÁ¢ÒìÇý¶¯Éú³¤£¬£¬£¬£¬£¬£¬ÔÚ¿¹Ìå¼°ÂѰ׵ÈÉúÎï´ó·Ö×ÓÒ©ÎïµÄÑз¢Ç°ÑØÁìÓò£¬£¬£¬£¬£¬£¬½¨ÉèÁ˹¦Ð§ÅäÌ×£¬£¬£¬£¬£¬£¬ÉèÊ©ÍêÉÆµÄÂѰ×ÖÊ/¿¹ÌåÒ©´ú¶¯Á¦Ñ§Ñо¿Æ½Ì¨£¬£¬£¬£¬£¬£¬ÉúÎï¼¼ÊõÒ©·ÇÈËÁ鳤ÀàÇå¾²ÆÀ¼Û¼¼ÊõЧÀÍÆ½Ì¨µÈ£¬£¬£¬£¬£¬£¬ÖúÁ¦°Ù°ÂÌ©µÈ¶à¸öÒ©ÆóÉúÎï¼¼ÊõÀàÒ©ÎïÁÙ´²Ç°Ñо¿µÄ¿ÆÑÐÏ£Íû¡£ ¡£¡£¡£¡£¡£

ÃÀ¸ß÷ףºØ°Ù°ÂÌ©»ñµÃ¡¶ÁÙ´²ÊÔÑé֪ͨÊé¡·£¬£¬£¬£¬£¬£¬Ï£ÍûBAT1308¿ÉÒÔÔÚ½ÓÏÂÀ´µÄÁÙ´²ÊÔÑéÖÐÓо«²ÊÌåÏÖ¡£ ¡£¡£¡£¡£¡£


ÁªÏµÃÀ¸ß÷
Email: marketing@medicilon.com.cn
µç»°: +86 (21) 5859-1500£¨×Ü»ú£©

Ïà¹ØÐÂÎÅ
Ö×ÁöÃâÒßÖÎÁƵĽø»¯£¡¶þ´úPD-1¿¹Ìå¼´½«³öÉú
2019-09-26
ÃÀ¸ß÷ÒÑÓë¶à¸ö¹«Ë¾ÔÚÖ×ÁöÃâÒßÒ©Î£¬£¬£¬£¬£¬ÈçADC£¬£¬£¬£¬£¬£¬PD-1£¬£¬£¬£¬£¬£¬Ë«¿¹Ò©ÎïµÈµÄÑз¢Àú³ÌÖÐÏàÖú¹²Ó®£¬£¬£¬£¬£¬£¬×ÊÖúËûÃÇÔÚÑз¢É걨Àú³ÌÖиü˳ËìµÄÄùâÁÙ´²Åú¼þ£¬£¬£¬£¬£¬£¬Íƶ¯Ñз¢Àú³Ì¡£ ¡£¡£¡£¡£¡£
º£ÄÚÖ×Áö»¼ÕßPD-1¿¹ÌåʹÓÃÇéÐÎÊÓ²ìÆÊÎö±¨¸æ
2016-03-04
2015Ä꣬£¬£¬£¬£¬£¬FDAÂ½ÐøÅú×¼PD-1ÒÖÖÆ¼ÁÓÃÓÚÐþÉ«ËØ°©¡¢·Î°©ºÍÉö°©µÄÖÎÁÆ£»£»£»£»±ðµÄÉÐÓиü¶à°©Ö¢ÀàÐÍÕýÔÚÆð¾¢ÉóÅúÖУ¬£¬£¬£¬£¬£¬ÉóÅú¹æÄ£ÏÕЩϯ¾íÁËËùÓÐʵÌåÁöµÄ¹æÄ££»£»£»£»
ÃâÒß¼ì²éµã×è¶ÏÁÆ·¨¸Ä±äÁ˰©Ö¢ÖÎÁƵķ¶Ê½£¬£¬£¬£¬£¬£¬´ËÑо¿ÖÐͨ¹ýÃÀ¸ß÷ÔÚ23 ¸öͬԴÖ×ÁöÄ£×ÓÖоÙÐÐÁË¿¹PD-1¿¹ÌåµÄÌåÄÚÑо¿
2023-07-06
Immune checkpoint blockade therapies have changed the paradigm of cancer therapies. Reseachers performed in vivo screening for anti-PD-1 therapy across 23 syngeneic tumor models and found that CT-26 and Colon 26, which are murine colorectal carcinoma derived from BALB/c mice, showed different sensitivity to anti-PD-1. In vivo studies for anti-PD-1 antibody across 23 syngeneic tumor models were performed by Medicilon.
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿